Innovus Pharma to Present at the Sachs BioCapital USA Forum at the New York Academy of Sciences
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage
pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve
men’s and women's health and respiratory diseases, today announced that Dr. Bassam Damaj, President and Chief Executive Officer and
Rauly Gutierrez, Vice President, Finance, will present at the Sachs BioCapital USA Forum in New York City on Wednesday, March 21,
2018. They will present an update on the Company’s growing revenues, the launch of new products and other of the Company’s business
plans.
Dr. Damaj and Mr. Gutierrez will also be meeting with members of the investment community and with potential business
development partners during one-on-one meetings at the conference as well. The corporate presentation will be available for
download on the Innovus Pharma web site (www.innovuspharma.com).
“We are honored to present at the New York Academy of Sciences and we look forward to updating the market on our growth and
discussing new business development opportunities with potential Company partners,” said Dr. Bassam Damaj, President and Chief
Executive Officer of Innovus Pharma.
About Conference Presentation time
Event: Sachs BioCapital USA Forum
Date: Wednesday, March 21, 2018
Time: 2:40 pm EST
Location: The Presenting Room, New York Academy of Sciences, 7 World Trade Center 250 Greenwich St., 40th Floor (D
Elevator Bank) New York, New York 10007
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve
men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial
partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing
prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com ; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com .
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information
contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties
that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, projected revenues from its various products, estimated market for its products, and
statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent
filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Innovus Pharma Investor Relations
Randy Berholtz
+1 858 249 7865
ir@innovuspharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005133/en/